Dyspnea Market: By Treatment Type (Supplemental Oxygen Therapy and Relaxation Therapy), By Drugs (Antianxiety, Antibiotics, Anticholinergic Agents, Corticosteroids, and Others), By Route of Administration (Oral, Inhalation, and Others), By End Users (Hospitals, Homecare, Specialty Clinics, Ambulatory Services, and Others) and Geography

The Dyspnea market size was valued at USD 6,748.2 million in 2023 and is expected to grow at 6.5% CAGR over the forecast period 2024 – 2030. The Dyspnea market pertains to the diagnosis, treatment, and management of various medical conditions that lead to difficulty in breathing, commonly known as dyspnea. Dyspnea is a distressing symptom that can arise from a multitude of underlying diseases, ranging from respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, interstitial lung diseases, and pulmonary hypertension, to cardiovascular conditions like heart failure and ischemic heart disease. This market encompasses a range of medical interventions, including medications, inhalers, pulmonary rehabilitation, oxygen therapy, and surgical procedures, all aimed at alleviating breathlessness and improving the quality of life for individuals afflicted by these conditions.

According to the World Health Organization (WHO), COPD is estimated to affect over 250 million people worldwide, causing approximately 3 million deaths annually. Asthma, a chronic respiratory disorder, affects around 235 million people globally, leading to over 380,000 deaths each year. The American Lung Association reports that interstitial lung diseases, a group of disorders affecting lung tissue, encompass over 200 different conditions and collectively contribute to significant morbidity and mortality. Pulmonary hypertension, a rare but serious condition affecting the arteries of the lungs, impacts an estimated 15 to 50 individuals per million population. Cardiovascular conditions are also a significant contributor to dyspnea. The Centers for Disease Control and Prevention (CDC) states that heart failure affects around 6.2 million adults in the United States alone, with an economic burden exceeding USD 30 billion annually. Ischemic heart disease, commonly known as coronary artery disease, remains a leading cause of death globally, contributing to approximately 8.9 million deaths annually. These statistics underscore the substantial impact of dyspnea-inducing diseases on individuals and healthcare systems, driving the ongoing research, development, and commercialization efforts within the Dyspnea market to improve patient outcomes and enhance respiratory well-being.

Dyspnea Market Key Developments:

• In July 2022, OMRON Healthcare introduced its latest advancement in the Oxygen therapy category with the launch of a portable oxygen concentrator. The product is designed to aid homecare providers when managing the therapy and lifestyle needs of nearly all patients with COPD and respiratory problems.
• In May 2022, Max Ventilator launched the multifunctional noninvasive ventilators which come with inbuild oxygen therapy and a humidifier.